Pre-Open Stock Movers 09/17: (CRVS) (ABCL) (BGNE) Higher; (PTGX) (GRTS) (X) Lower (more...)

September 17, 2021 9:28 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Pre-Open Stock Movers:

Corvus Pharma (NASDAQ: CRVS) 70.5% HIGHER; Surge After AstraZeneca's (NASDAQ: AZN) CD73 Results at ESMO

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) 56.4% LOWER; announced the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that Protagonist's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold.

AbCellera (Nasdaq: ABCL) 15% HIGHER; announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab (LY-CoV016) 1400 mg to include post-exposure prophylaxis (PEP) to prevent SARS-CoV-2 infection or symptomatic COVID-19. The neutralizing antibodies, which were authorized together by the FDA in February 2021 to treat early COVID-19 infection, can now also be used together to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination, and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting, including a nursing home or prison.

BeiGene (NASDAQ: BGNE) 10% HIGHER; announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenstr├â┬Âms macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy.

Arcus Biosciences (NYSE: RCUS) 5.9% HIGHER; Surge After AstraZeneca's (NASDAQ: AZN) CD73 Results at ESMO

Gritstone bio, Inc. (Nasdaq: GRTS) 5.1% LOWER; announced a $55.0 million private investment in public equity (PIPE) financing from the sale of 5,000,000 shares of its common stock at a price per share of $11.00. Gross proceeds from the PIPE financings total $55.0 million, before deducting placement agent fees and offering expenses. The PIPE is being led by Frazier Life Sciences Public Fund, with additional participation from Redmile Group and Gilead Sciences.

Diamondback Energy, Inc. (NASDAQ: FANG) 4.9% HIGHER; announced that it has accelerated its plans to return 50% of Free Cash Flow to stockholders to the fourth quarter of 2021, and the Board of Directors has approved an up to $2.0 billion share repurchase program to complement this return commitment.

Berkeley Lights, Inc. (NASDAQ: BLI) 4.5% HIGHER; Cathie Wood's ARK buys on dip

Rockley Photonics Holdings Ltd (NYSE: RKLY) 2.7% HIGHER; BofA Securities initiates coverage with a Buy rating and a price target of $14.00.

ZoomInfo Technologies (NASDAQ: ZI) 2.4% HIGHER; Barclays upgraded from Equalweight to Overweight with a price target of $83.00.

UiPath Inc. (NYSE: PATH) 2% HIGHER; Barclays upgraded from Equalweight to Overweight with a price target of $83.00.

United States Steel Corporation (NYSE: X) 1.9% LOWER; today provided third quarter 2021 guidance. Third quarter 2021 adjusted EBITDA is expected to be approximately $2.0 billion. This compares to second quarter 2021 adjusted EBITDA of approximately $1.3 billion.

Take-Two Interactive (NASDAQ: TTWO) 1.4% LOWER; BMO Capital downgraded from Outperform to Market Perform with a price target of $150.00 (from $225.00).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

BMO Capital, Barclays, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA, ARK